Introduction: Sepiapterin reductase deficiency (SRD) is an exceedingly rare neurotransmitter disease caused by an enzyme error involved in the synthesis of tetrahydrobiopterin (BH4). It has been described in nearly 60 cases so far. The clinical manifestations include motor and speech delay, axial hypotonia, dystonia, weakness, oculogyric crises, diurnal fluctuation, and improvement of symptoms during sleep. Molecular genetic analysis can demonstrate pathogenic mutations in the SPR gene, allowing for a definitive diagnosis. Levodopa/carbidopa and 5-hydroxytryptophan are used for treatment. Case Presentation: We present a 19-year-old male patient who was evaluated for dysarthria, axial hypotonia, limb dystonia, and movement disorder. The parents described the current patient’s history with febrile seizures since 9 months of age, as well as speech and neuromotor developmental retardation, which indicated that the disease began in infancy. The basal metabolic work-up was normal except for hyperprolactinemia. The definitive diagnosis of SRD was confirmed by whole exome sequencing (WES) analysis, which revealed a homozygous pathogenic mutation c.655C>T (p.Arg219*) (rs779204655) in the SPR gene. After treatment, we noted significant improvements in dystonia, axial hypotonia, and dysarthria. Conclusion: WES analysis offers a more expeditious and dependable method for diagnosing difficult cases exhibiting neurodevelopmental problems and thus renders the possibilities of early management.

AlSubhi S, AlShahwan S, AlMuhaizae M, AlZaidan H, Tabarki B. Sepiapterin reductase deficiency: report of 5 new cases. Eur J Paediatr Neurol. 2017 May;21(3):583–6.
Blau N, Bonafé L, Thöny B. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. Mol Genet Metab. 2001 Sep-Oct;74(1-2):172–85.
Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet. 2001 Aug;69(2):269–77.
Carducci C, Santagata S, Friedman J, Pasquini E, Carducci C, Tolve M, et al. Urine sepiapterin excretion as a new diagnostic marker for sepiapterin reductase deficiency. Mol Genet Metab. 2015 Aug;115(4):157–60.
Delanne J, Bruel AL, Huet F, Moutton S, Nambot S, Grisval M, et al. The diagnostic rate of inherited metabolic disorders by exome sequencing in a cohort of 547 individuals with developmental disorders. Mol Genet Metab Rep. 2021 Oct 18;29:100812.
Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V, et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012 Apr;71(4):520–30.
Froukh T. Genetic study in a family with dopa-responsive dystonia revealed a novel mutation in sepiapterin reductase gene. Pak J Med Sci. 2019 Nov-Dec;35(6):1736–9.
Koht J, Rengmark A, Opladen T, Bjørnarå KA, Selberg T, Tallaksen CM, et al. Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene. Acta Neurol Scand. 2014;129(198):7–12.
Kritioti E, Theodosiou A, Parpaite T, Alexandrou A, Nicolaou N, Papaevripidou I, et al. Unravelling the genetic causes of multiple malformation syndromes: a whole exome sequencing study of the Cypriot population. PLoS One. 2021 Jul 29;16(7):e0253562.
Nakagama Y, Hamanaka K, Mimaki M, Shintaku H, Miyatake S, Matsumoto N, et al. Leaky splicing variant in sepiapterin reductase deficiency: are milder cases escaping diagnosis?Neurol Genet. 2019 Mar 25;5(2):e319.
Opladen T, López-Laso E, Cortès-Saladelafont E, Pearson TS, Sivri HS, Yildiz Y, et al. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. Orphanet J Rare Dis. 2020 May 26;15(1):126.
Shalash AS, Rösler TW, Müller SH, Salama M, Deuschl G, Müller U, et al. c.207C[{GT}]G mutation in sepiapterin reductase causes autosomal dominant dopa-responsive dystonia. Neurol Genet. 2017 Nov 1;3(6):e197.
Thöny B, Heizmann CW, Mattei MG. Human GTP-cyclohydrolase I gene and sepiapterin reductase gene map to region 14q21-q22 and 2p14-p12, respectively, by in situ hybridization. Genomics. 1995 Mar 1;26(1):168–70.
Wu Y, Chen P, Sun L, Yuan S, Cheng Z, Lu L, et al. Sepiapterin reductase: characteristics and role in diseases. J Cell Mol Med. 2020 Sep;24(17):9495–506.
Zahra C, Tabone C, Camilleri G, Felice AE, Farrugia R, Bezzina Wettinger S. Genetic causes of Parkinson’s disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPR. BMC Med Genet. 2016 Sep 9;17(1):65.
You do not currently have access to this content.